Bentyl (Dicyclomine) for Irritable Bowel Syndrome
Bentyl (dicyclomine) is a first-line anticholinergic antispasmodic that may be effective for global IBS symptoms and abdominal pain, though the evidence supporting its use is weak, and common anticholinergic side effects (dry mouth, visual disturbance, dizziness) frequently limit tolerability. 1
Dosing and Administration
Standard dosing is 40 mg four times daily (160 mg/day total), which was the regimen used in controlled trials 2. However, this dose frequently requires reduction due to side effects:
- Initial dose: Start at 40 mg four times daily
- Dose adjustment: In clinical trials, 46% of patients with side effects required dose reduction to an average of 90 mg daily while maintaining clinical benefit 2
- Timing: Can be taken before meals for postprandial symptoms 3
- Duration: Use intermittently during periods of increased pain rather than indefinitely 3
The drug reaches peak plasma concentrations within 60-90 minutes, with a half-life of approximately 1.8 hours 2.
Clinical Efficacy
In controlled trials, 82% of patients treated with dicyclomine 160 mg daily showed favorable clinical response versus 55% on placebo (p<0.05) 2. The drug demonstrated superiority over placebo for:
- Overall patient condition improvement
- Decreasing abdominal pain and tenderness
- Improving bowel habits 4
However, the 2021 British Society of Gastroenterology guidelines rate antispasmodics as having only weak recommendation strength with very low quality evidence 1. Meta-analysis showed dicyclomine (along with cimetropium) had the most significant pain improvement among antispasmodics, though this benefit must be weighed against side effects 5.
Contraindications (Absolute)
Per FDA labeling, dicyclomine is absolutely contraindicated in 2:
- Obstructive uropathy
- Obstructive gastrointestinal disease
- Severe ulcerative colitis
- Reflux esophagitis
- Unstable cardiovascular status in acute hemorrhage
- Glaucoma
- Myasthenia gravis
- Prior hypersensitivity to dicyclomine
- Infants less than 6 months of age
- Nursing mothers
Common Adverse Effects
Anticholinergic side effects occur in 61% of patients at the 160 mg daily dose 2:
- Dry mouth: 33% (versus 5% placebo)
- Dizziness: 29% (versus 2% placebo)
- Blurred vision: 27% (versus 2% placebo)
- Nausea: 14%
- Light-headedness: 11%
- Drowsiness: 9%
- Weakness: 7%
- Nervousness: 6%
Nine percent of patients discontinued treatment due to side effects (compared to 2% on placebo) 2. However, in 41% of patients experiencing side effects, these either disappeared or became tolerable without dose reduction 2.
Clinical Positioning
Dicyclomine functions as a first-line agent in the IBS treatment algorithm 1, positioned after:
- Lifestyle modifications (regular exercise)
- First-line dietary advice
- Soluble fiber supplementation (if appropriate)
If dicyclomine fails or is not tolerated, escalate to second-line therapies: tricyclic antidepressants (starting with 10 mg amitriptyline at bedtime, titrating to 30-50 mg) provide stronger evidence (moderate quality) for global symptoms and abdominal pain 1.
Important Caveats
- Avoid in constipation-predominant IBS due to anticholinergic effects that may worsen constipation 5
- The drug has 1/8 the anticholinergic potency of atropine at muscarinic receptors but also exerts direct smooth muscle relaxation 2
- Use intermittently rather than continuously when possible—reserve for symptomatic periods or predictable triggers 3
- Side effects typically occur early; if tolerable initially, many patients adapt over time 2
- The 2000 BSG guidelines noted dicyclomine as one of the more effective antispasmodics for pain, but the common side effect of dry mouth limits use 5